Age-grouped differences in adverse drug events from psychotropic medication

Journal of Child and Adolescent Psychopharmacology

Volumn 21, Issue 4, 2011, Pages 299-309

  Safer, Daniel J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ARIPIPRAZOLE; ATOMOXETINE; CARBAMAZEPINE; CLOZAPINE; DIPHENHYDRAMINE; ETIRACETAM; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; NEUROLEPTIC AGENT; OLANZAPINE; PHENOBARBITAL; PHENYTOIN; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDAL; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE; ZOLPIDEM; ZOLPIDEM TARTRATE; ZONISAMIDE;

ABDOMINAL PAIN; AFFECT; AGE SPECIFIC CARE; AGITATION; ALERTNESS; AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; APPETITE; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR CHANGE; BLOOD PRESSURE; BODY GROWTH; BRAIN MATURATION; CARDIOVASCULAR RISK; CONTROLLED CLINICAL TRIAL (TOPIC); DEVELOPMENTAL STABILITY; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG ERUPTION; DRUG FORMULATION; DRUG RESPONSE; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; ELECTROCARDIOGRAM; EUPHORIA; EXCITABILITY; GINGIVA HYPERPLASIA; GROWTH RATE; GROWTH RETARDATION; HALLUCINATION; HEIGHT; HORMONE RELEASE; HOSTILITY; HUMAN; HYPERHIDROSIS; HYPERSALIVATION; HYPERTHERMIA; INSULIN RESISTANCE; INTELLECTUAL IMPAIRMENT; IRRITABILITY; LIVER FUNCTION TEST; LIVER TOXICITY; METABOLIC ACIDOSIS; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; OVARY POLYCYSTIC DISEASE; PANCREATITIS; PHYSICAL ACTIVITY; QT PROLONGATION; REVIEW; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; TACHYCARDIA; TIC; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE FACTORS; CHILD; DRUG TOXICITY; FEMALE; HUMANS; MALE; MEDICATION ERRORS; PHARMACEUTICAL PREPARATIONS; PSYCHOTROPIC DRUGS;

EID: 80052099080     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2010.0152     Document Type: Review

References (168)

1. Abilify FDA approved label: 2009. p. 39. Available at www .accessdata.fda.gov/drugsatFDA-docs/label/2009/021436s027lbl .pdf (accessed 3/11).
2. Ahmann PA, Theye FW, Berg R, Linquist AJ, VanErem A, Campbell LR: Placebo-controlled evaluation of amphetamine mixture- Dextroamphetamine salts and amphetamine salts (Adderall): Efficacy rate and side effects. Pediatrics107:e10, 2001.
3. Ahmann PA, Waltonen SJ, Olson KA, Theye FW, VanErem AJ, LaPlant RJ: Placebo-controlled evaluation of Ritalin side effects. Pediatrics 91:1101-1106, 1993.
4. Alfaro C: 2007. Clinical review NDA 020-592 S 040 Zyprexa (olanzapine) Available at www.fda.gov/downloads/advisoryCommittees/ CommitteesMeeting/ Materials/Drugs/PsychopharmcologicDrugs/ AdvisoryCommittee/UCM164423.pdf (assessed 10/4/2010).
5. Aman MG, Arnold LE, McDougle CJ, Vitiello B, Scahill L, Davies M, McCracken DM, Tierney E, Nash PL, Posey DJ, Chuang S, Martin A, Shah B, Gonzalez NM, SWiezy NB, Ritz L, McGough J, Ghuman JK. Lindsay RL: Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol 15:869-884, 2005.
6. Ambien FDA Approved Label: 2008. pp. 3 and 12. Available at www.accessdata.fda.gov/drugsatfda-docs/label/2008/019908s027lbl .pdf (accessed 3/11).
7. Ambien Zolpidem) BPCA Clinical Review Summary Available at www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4399b1-00-Index.http://www.fda. gov/ohrms/dockets/ac/08/briefing/2008-4399b1-00-Index.html accessed 3/11
8. Amsterdam JD, Shults J: Comparison of short-term venlafaxine versus lithium monotherapy versus lithium monotherapy for bipolar II major depressive episode. J Clin Psychopharmacol 28:171-181, 2008.
9. Amsterdam JD, Shults J: Efficacy and safety of long-term fluoxetine versus lithum monotherapy of bipolar II disorder: A randomized, double-blind, placebo-substitution study. Am J Psychiatry 167:792-800, 2010.
10. Anderson GD: Children versus adults: Pharmacokinetic and adverseeffect differences. Epilepsia 43 (Suppl 3):53-59, 2002.
11. Aronson JK (ed.): Meyler's Side Effects of Drugs, 6th edition. New York: American Elsevier Publishing Co.; 2006; p. 282.
12. Barbui C, Esposito E, Cipriani A: Selective serotonin reuptake inhibitors and risk of suicide: A systematic review of observationalstudies. CMAJ 180:291-297, 2009.
13. Barkley RA, McMurray MB, Edelbrock CS, Robbins K: Side effects of methylphenidate in children with attention deficit hyperactivity disorder: A systemic, placebo-controlled evaluation. Pediatrics 86:184-192, 1990.
14. Belgorosky A, Rivarola MA: Changes in serum sex hormone-binding globulin and in serum non-sex hormone-binding globulin-bound testosterone during prepuberty in boys. J Steroid Biochem 27:291-295, 1987.
15. Benes M, Turtle M, Khan Y, Farol P: Myelination of a key relay zone in the hippocampal formation occurs in the human brain during childhood, adolescence, and adulthood. Arch Gen Psychiatry 51:477-484, 1994.
16. Benjamin DK, Smith B, Sun JM, Murphy MD, Avant D, Mathis L Rodriguez W, Califf RM, Li JS: Safety and transparency of pediatric drug trials. Arch Pediat Adolesc Med 163:1080-1086, 2009.
17. Biederman J, Mick, E, Hammerness P, Harpold MA, Aleardi M, Dougherty M, Wozniak J: Open-label, 8 week trial of olanzapine for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry 58:589-594, 2005a.
18. Biederman J, Spencer T, Surman C, Mick E, Dunkel S, Dougherty M: A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Poster presented at the annual meeting of the Am Psychiatric Assoc., Atlanta, GA, May 2005b.
19. Blair J, Scahill L, State M, Martin A: Electrocardiographic changes in children and adolescents treated with ziprasidone: A prospective study. J Am Acad Child Adolesc Psychiatry 44:73-79, 2005.
20. Blumer JL, Findling RL, Shih WJ, Soubrane C, Reed MD: Controlled clinical trial of zolpidem for the treatment of insomnia associated with attention-deficit/hyperactivity disorder in children 6 to 17 years of age. Pediatrics 173:e770-e777, 2009.
21. Boorin S, Scahill L, Caprio S, Jeon S, Zawalich W, Nicol G: Cardiometabolic consequences of risperidone in children with autism. Poster presented at the annual meeting of the Am Acad Child Adolesc Psychiatry, New York City, October 2010.
22. Bourgeois FT, Mandi KD, Valim C, Shannon MW: Pediatric adverse drug events in the outpatient setting; an 11-year national analysis. Pediatrics 124:e744-e750, 2009.
23. Bourgeois FT, Shannon MW, Valim C, Mandl KD: Adverse drug events in the outpatient setting: An 11-year national analysis. Pharmacoepidemol Drug Saf 19:901-910, 2010.
24. Brent RL, Tanski S, Weitzman M: A pediatric perspective on the unique vulnerability and resilience of the embryo and the child to environmental toxicants: The importance of the rigorous research concerning age and agent. Pediatrics 113:935-944, 2004.
25. Bridge JA, Birmaher B, Iyengar S, Barbe RP, Brent DA: Placebo response in randomized trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry 166:42-49, 2009.
26. Calabrese JR, Sulllivan JR, Bowden CL, Suppes T, Goldberg JF, Sachs GS, Shelton MD, Goodwin FK, Frye MA, Kusumakar V: Rash in multicenter trials of lamotrigine in mood disorders: Clinical relevance and management. J Clin Psychiatry 63:1012-1019, 2002.
27. Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JF: Neuroleptic-related dyskinesias in autistic children; a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 36:835-843, 1997.
28. Campbell M, Silva RR, Kafantaris V, Locascio JJ, Gonzolez NM, Lee D, Lynch CS: Predictors of side effects associated with lithium administration in children. Psychopharm Bull 27:373-380, 1991.
29. Carlson GA, Mick E: Drug-indused disinhibition in psychiatrically hospitalized children J Child Adolesc Psychopharmacol 13:153-163, 2003.
30. Casetta I, Granieri E, Desidera M, Monetti VC, Tola MR, Paolino E, Govoni V, Calura G: Phenytoin-induced gingival overgrowth: A community-based cross-sectional study in Ferrara, Italy. Neuroepidemiology 16:296-303, 1997.
31. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT: Secondgeneration antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 14:372-394, 2004.
32. Cohen LJ, Jermain DM: Neuropsychopharmacology: 1. Basic principles. In: Textbook of Pediatric Neuropsychiatry. Edited by CE. Coffey, RA. Brumback. Washington DC: American Psychiatric Press; 1998; pp. 1275-1286.
33. Correll CU, Kane JM: One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: A systematic review. J Child Adolesc Psychopharmacol 17:647-656, 2007.
34. Correll CU, Lops J, Kane JM, Malhotra AK, Manu P: Electrocardiographic changes with ziprasidone in children and adolescents treated within the adult dose range: An open-label prospective study. Poster presented at the annual meeting of the Am Psychiatric Assoc., Washington, DC, May 2008.
35. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302:1765-1773, 2009.
36. Coskun M, Zoroglu S: Efficacy and safety of fluoxetine in preschool children with obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 19:297-300, 2009.
37. Cueva JE, Overall JE, Small AM, Armenteros JL, Perry R, Campbell M: Carbamazepine in aggressive children with conduct disorder: A double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 35:480-490, 1996.
38. Cutler GB: The role of estrogen in bone growth and maturation during childhood and adolescence. J Steroid Biochem Mol Biol 61:141-144, 1997.
39. Dannon PN, Iancu I, Lowengrub K, Gonopolsky Y, Musin E, Grunhaus L, Kokler M: A naturalistic long-term comparison of selective serotonin reuptake inhibitors in the treatment of panic disorder. Clin Neuropharmacol 30:326-334, 2007.
40. Daughton JM, Kratochvil CJ, Vaughan B, Barker A: Long-acting stimulant treatment of ADHD in young children. Poster presented at the annual meeting of the Am Acad Child Adolesc Psychiatry, Honolulu, HI, October 2009.
41. DelBello MP, Findling RL, Kushner S, Wang D, Olson W H, Capece JA, Fazzio L, Rosenthal NR: A pilot controlled trial of topirimate for mania in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 44:539-547, 2005.
42. Demyttenaere K, Jaspers L: Review: Bupropion and SSRI-induced side effects. J Psychopharmacol 22:792-804, 2008.
43. de Leon J, Susce MT, Johnson M, Hardin M, Pointer L, Ruano G, Windemuth A, Diaz FJ: A clinical study of the association of antipsychotics with hyperlipidemia. Schiz Res 92:95-102, 2007.
44. deWit H, Enggasser JL, Richards JB: Acute administration of d-amphetamine decreases impulsivity in healthy volunteers. Neuropsychopharmacology 25:813-825, 2002.
45. DiFranza JR, Richmond JB: Let the children be heard: Lessons from studies of the early onset of tobacco addiction. Pediatrics 171:623-624, 2008.
46. Diphenhydramine Official FDA Information: 2009. Side effects and uses. Available at www.drugs.com/pro/diphenhydramine.html (assessed 2/28/11).
47. Donnelly CL, Bangs M, Trzepacz P, Jin L, Zhang S, Witte MM, Ball SG, Spenser TJ: Long-term safety and tolerability of atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder: Follow-up to 4 years. Poster presented at the annual meeting of the Am Acad Child Adolesc Psychiatry, Chicago, IL, October 2008.
48. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB: Valproic acid hepatic fatalities: A retrospective review. Neurology 37:379-385, 1987.
49. Dunbar F, Kusumakar V, Daneman D, Schulz M: Growth and sexual maturation during long-term treatment with risperidone. Am J Psychiatry 161:918-920, 2004.
50. Efron D, Jarman F, Barker M: Side effects of methylphenidate and dextroamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial. Pediatrics 100:662-666, 1997.
51. Faraone SV, Spencer TJ, Kollins SH, Glatt SJ: Effects of lisdexamfetamine dimesylate treatment for ADHD on growth. J Am Acad Child Adolesc Psychiatry 49:24-32, 2010.
52. Farwell JR, Lee YJ, Hirtz DG, Sulzbacher SI, Ellenberg JH, Nelson KB: Phenobarbital for febrile seizures-Effects on intelligence and on seizure recurrence. NEJM 322:364-369, 1990.
53. FDA Pediatric Labeling Changes: Through September 20, 2010. www.fda.gov/downloads/ScienceResearch/SpecialTopics/Pediatric TherapeuticResearch/UCM163159.pdf (accessed 11/2010). Topamax 12/22/2009, p.9; Zyprexa 12/4/2009, pp 9 and 25; Seroquel 12/2/2009, p. 10; Prozac 2/18/2005, p.66. Effexor 2/18/2005, p.64
54. Findling RL, Johnson JL, McClellan J, Frazier JA, Vitiello B, Hamer RM, Lieberman JA, Ritz L, McNamara NK, Lingler J, Hlastala S, Pierson L, Puglia M, Maloney AE, Kaufman EM, Noyes N, Sikich L: Double-blind maintenance safety and effectiveness findings from the treatment of early-onset schizophrenia spectrum (TEOSS) study. J Am Acad Child Psychiatry 49:583-594, 2010.
55. Firestone P, Musten LM, Pisterman S, Mercer J, Bennett S: Shortterm side effects of stimulant medication are increased in preschool children with attention-deficit/hyperactivity disorder: A doubleblind placebo-controlled study. J Child Adolesc Psychopharmacol 8:13-25, 1998.
56. Fleischhacker WW, Lemmens P, van Baelen B: A qualitative assessment of the neurological safety of antipsycotic drugs: An analysis of a risperidone database. Pharmacopsychiatry 34:104-110, 2001.
57. Fraguas D, Correll CU, Merchan-Naranjo J, Rapado-Castro M, Parellada M, Moreno C, Arango C: Efficacy and safety of secondgeneration antipsychotics with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 2010 [Epub ahead of print].
58. Friedman RA, Leon AC: Expanding the black box-Depression, antidepressants, and the risk of suicide. N Engl J Med 356:2343-2346, 2007.
59. Gadde KM, Yonish GM, Wagner HR, Foust MS, Allison DB: Atomoxetine for weight reduction in obese women: A preliminary randomized controlled trial. Int J Obes 30:1138-1142, 2006.
60. Gestner T, Busing D, Bell N, Longin E, Kasper JM, Klostermann W, Hering B, Hanefeld F, Eckel U, Hoffmann R, Bettendorf U, Weidner B, Wiemer-Kruel A, Brockmann K, Neumann FW, Sandrieser T, Wolff M, Konig S: Valproic acid-induced pancreatitis: 16 new cases and a review of the literature. J Gastroenterol 42:39-48, 2007.
61. Ghuman JK, Ginsberg GE, Subramaniam G, Ghuman HS, Kau AS, Riddle MA: Psychostimulants in preschool children with attentiondeficit/ hyperactivity disorder: Clinical evidence from a developmental disorders institurion. J Am Acad Child Adolesc Psychiatry 40:516-524, 2001.
62. Glauser TA: Behavioral and psychiatric adverse events associated with antiepileptic drugs commonly used in pediatric patients. J Child Neurol 19 (Suppl 1):S25-S38, 2004.
63. Goodman DW, Scheckner B, Dirks B, Babcock T, Adeyi B, Lasser R, Gasior M, Findling R: Safety profile of lisdexamfetamine dimesylate in clinical trials in children, adolescents, and adults with attention-deficit/hyperactivity disorder. Poster presented at the annual meeting of the Am Psychiat Assoc., New Orleans, May 2010.
64. Graae F, Milner J, Rizzotto L, Klein RG: Clonazepam in childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 33:372-376, 1994.
65. Green WH: Child and Adolescent Clinical Psychopharmacology 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2007.
66. Greenhill LL, Posner K, Vaughan BS, Kratochvil CJ: Attention deficit hyperactivity disorder in preschool children. Child Adolesc Psychiatr Clin N Am 17:347-366, 2008.
67. Guberman AH, Besag FM, Brodie MJ, Dooley JM, Duchowny MS, Pellock JM, Richens A, Stern RS, Trevathan E: Lamotrigine-associated rash: Risk/benefit considerations in adults and children. Epilepsia 40:985-991, 1999.
68. Gupta A, Waldhauser LK: Adverse drug reactions from birth to early childhood. Pediatr Clin N Am 44:79-92, 1997.
69. Hammad TA, Laughren T, Racoosin J: Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63:332-339, 2006.
70. Harada T, Sakamoto K, Ishigooka J: Incidence and predictors of activation syndrome induced by antidepressants. Depress Anxiety 25:1014-1019, 2008.
71. Hardin CL: Therapeutic safety monitoring: What to look for and when to look for it. Epilepsia 41(Suppl 8):S37-S44, 2000.
72. Hay AD, Heron J, Ness A: The prevalence of symptoms and consultations in pre-school children in the Avon longitudianal study of parents and children (ALSPAC): A prospective cohort study. Fam Pract 22:367-374, 2005.
73. Hazell L, Shakir SA: Under-reporting of adverse drug reactions. Drug Safety 29:385-396, 2006.
74. Hazell P, Becker K, Nikkanen EA, Trzepacz PT, Tanaka Y, Tabas L, D'Souza D, Witcher J, Long A, Ponsler G, Dittmann RW: Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Poster presented at the annual meeting of the Am Acad Child Adolesc Psychiatry, Chicago, IL, October 2008.
75. Heim K: The use of therapeutics in adolescence. J Adolesc Health Care 8:8-35, 1987.
76. Hellings JA, Weckbaugh M, Nickel EJ, Cain SE, Zarcone JR, Reese M, Hall S, Ermer DJ, Tsai LY, Schroeder SR, Cook EH: A doubleblind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 15:682-692, 2005.
77. Inaba DS, Cohen WE: Uppers, Downers; All Arounders. 4th ed. Ashland, OR: CNS Publications; 2000; p.58.
78. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV: Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 329:1383-1388, 1993.
79. Jamner LD, Whalen CK, Loughlin SE, Mermelstein R, Audrain- McGovern J, Krishnan-Sarin S, Worden JK, Leslie FM: Tobacco use across the formative years: A road map to developmental vulnerabilities. Nicotine Tob Res 5 (Suppl 1): S71-S87, 2003.
80. Joffe H, Cohen LS, Suppes T, McLaughlin WL, Lavori P, Adams JM, Hwang CH, Hall JE, Sachs GS: Valproate is associated with newonset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 59:1078-1086, 2006.
81. Kane JM: Tardive dyskinesia in the elderly: Data from a prospective study. Psychiatric Annals 32:233-236, 2002.
82. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE: Developmental pharmacology-Drug disposition, action and therapy in infants and children. NEJM 149:1157-1167, 2003.
83. Keepers GA, Casey DE: Prediction of neuroleptic-induced dystonia. J Clin Psychopharmacol 7:342-345, 1987.
84. Khurana DS, Riviello J, Helmers S, Holmes G, Anderson J, Mikati MA: Efficacy of gabapentin therapy in children with refractory partial seizures. J Pediatr 128:829-833, 1996.
85. Koenig SA, Buesing D, Longin E, Oehring R, Haussermann P, Kluger G, Lindmayer F, Hanusch R, Degen I, Kuhn H, Samii K, Jungck A, Bruckner R, Seitz R, Boxtermann W, Weber Y, KnappR, Richard HH, Weidener B, Kasper JM, Haensch CA, Fitzek S: Valproic acidinduced hepatopathy: Nine new fatalities in Germany from 1994 to 2003. Epilepsia 47:2027-2031, 2006.
86. Kooij JJ, Burger H, Boonstra AM, Van Der Linden PD, Kalma LE, Buitelaar JK: Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder: A randomized placebo- controlled double-blind cross-over trial. Psychol Med 34:973-982, 2004.
87. Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Baker KD, Feldman PD, Gelowitz DL: Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:919-927, 2006.
88. Kryzhanovskaya LA, Robertson-Plouch CK, Xu W, Carlson JL, Merida KM, Dittmann RW: The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: A pooled analysis of 4 clinical trials. J Clin Psychiatry 70:247-258, 2009.
89. Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Lenane M, Hamburger SD, Smith AK, Albus KE, Alaghband-Rad J, Rapoport JL: Childhood-onset schizophrenia: A double-blind clozapine- haloperidol comparison. Arch Gen Psychiatry 53:1090-1097, 1996.
90. Laita P, Cifuentes A, Doll A, Llorente C, Cortes I, Parellada M, Moreno D, Ruiz-Sancho A, Graell M, Arango C: Antipsychoticrelated abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. J Child Adolesc Psychopharmacol 17:487-502, 2007.
91. Leckman JF, Cohen DJ, Shaywitz BA, Caparulo BK, Heninger GR, Brown MB: CSF monoamine metabolites in child and adult psychiatric patients. Arch Gen Psychiatry 37:677-681, 1980.
92. Lee DO, Steingard RJ, Cesena M, Helmers SL, Riviello JJ, Mikati MA: Behavioral side effects of gabapentin in children. Epilepsia 37:87-90, 1996.
93. Lipkin PH, Goldstein IJ, Adesman AR: Tics and dyskinesias associated with stimulant treatment in attention-deficit-hyperactivity disorder. Arch Pediat Adolesc Med 148:859-861, 1994.
94. Liu AH, Jaramillo R, Sicherer SH, Wood RA, Bock A, Burks AW, Massing M, Cohn RD, Zeldin DC: National prevalence and risk factors for food allergy and relationship to asthma: Results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol 126:798-806, 2010.
95. Livingston S, Pruce I, Pauli LL, Livingston H: Managing side effects of antiepileptic drugs. Pediatr Ann 8:97-102, 1979.
96. Locke TF, Newcomb MD: Alcohol involvement and dysphoria: A longitudinal examination of gender differences from late adolescence to adulthood. Psychol Addict Behav 15:227-236, 2001.
97. Maayan L, Vakhrusheva J, Scheridan EM, Correll C: Efficacy and tolerability of risperidone across the age span: A meta-analytic comparison of placebo-controlled trials. Poster presented at the New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL, June 2010.
98. MacKay FJ, Wilton LV, Pearce GL, Freemantle SM, Mann RD: Safety of long-term lamotrigine in epilepsy. Epilepsia 38:881-886, 1997.
99. Majola MP, McFadyen ML, Connally C, Nair YP, Govender M. Laher MH: Factors influencing phenytoin-induced gingival enlargement. J Clin Periodontol 27:506-512, 2000.
100. Malone RP, Delaney MA, Luebbert JF, Cater J, Campbell M: A double-blind placebo controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry 57:649-654, 2000.
101. McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, Merideth C, Nordenhem A, Young AH: A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 71:163-174, 2010.
102. Miceli JJ, Tensfeldt TG, Shiovitz T, Anziano R, O'Gorman C, Harrigan RH: Effects of oral ziprasidone and oral haloperidol on QTc interval in patients with schizophrenia or schizoaffective disorder. Pharmacotheraphy 30:127-135, 2010.
103. Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R: Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics 123:611-616, 2009.
104. Murry DJ, Crom WR, Reddick WE, Bhargava R, Evans WE: Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos 23:1110-1116, 1995.
105. Nilsson M, Joliat MJ, Miner CM, Brown EB, Heiligenstein JH: Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents. J Child Adolesc Psychophamacol 14:412-417, 2004.
106. Owens DGC: A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs. New York: Cambridge University Press; 1999.
107. Papanikolaou PN, Churchill R, Wahlbeck K, Ioannidis JP: Safety reporting in randomized trials of mental health interventions. Am J Psychiatry 16:1692-1697, 2004.
108. Paterson R, Douglas C, Hallmayer J, Hagan M, Krupenia Z: A randomized, double-blind, placebo-controlled trial of dextroamphetamine in adults with attention deficit hyperactivity disorder. Aust NY J Psychiatry 33:494-502, 1999.
109. Paus T, Zijdenbos A, Worsley K, Collins DL, Blumenthal J, Giedd JN, Rapoport JL, Evans AC: Structural maturation of neural pathways in children and adolescents: In vivo study. Science 283:1908- 1911, 1999.
110. Pellock JM: Carbamazepine side effects in children and adults. Epilepsia 28 (Suppl 3):S64-S70, 1987.
111. [PDR] Physician's Desk Reference 62nd ed. Montvale, NJ: Thomson Healthcare; 2008;p. 877.
112. Poulton A: Growth on stimulant medication; clarifying the confusion: A review. Arch Dis Child 90:801-806, 2005.
113. Provigil FDA Approved Label: 8/17/2007. p. 12. Available at www.accessdata.fda.gov/drugsatfda-docs/label/2007/020717s020s013s018lbl.pdf (accessed 3/11).
114. Rancurello MD, Vallano G, Waterman GS: Psychotropic drug-induced dysfunction in children. In: Drug-Induced Dysfunction. Edited by MS. Keshavan, JS. Kennedy. New York: Hemisphere Publ. Corp.; 1992; pp. 75-92.
115. Rapoport JL, Buchsbaum MS, Weingartner H, Zahn TP, Ludlow C, Mikkelsen EJ: Dextroamphetamine: Its cognitive and behavioral effects in normal and hyperactive boys and normal men. Arch Gen Psychiatry 37:933-943, 1980.
116. Realmuto GM, Erickson WD, Yellin AM, Hopwood JH, Greenberg LM: Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. Am J Psychiatry 141:440-442, 1984.
117. Reinisch JM, Sanders SA, Mortensen EL, Rubin DB: In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA 274:1518-1525, 1995.
118. Reiter E, Feucht M, Hauser E, Seidl R: Changes in body mass index during long-term topiramate therapy in pediatric epilepsy patients- A retrospective analysis. Seizure 13:491-493, 2004.
119. Remeron FDA Approved Label: 2/12/2008. p. 11. Available at www.accessdata.fda.gov/drugsatFDA-docs/label/2007/020415s019 , 021208s010lbl.pdf (accessed 3/11).
120. Risperidal FDA Approved Label: 12/22/2009, pp. 17-18, 33. Available at www.accessdata.fda.gov/drugsatfda-docs/label/2009/020272s056,020588s044, 021346s033,021444s03lbl.pdf
121. Rynn MA, Riddle MA, Yeung PP, Kunz NR: Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: Two placebo-controlled trials. Am J Psychiatry 164:290-300, 2007.
122. Safer DJ: A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharnacol 24:429-436, 2004.
123. Safer DJ, Allen RP, Barr E: Depression of growth in hyperactive children on stimulant drugs. N Eng J Med 287:217-220,1972.
124. Safer DJ, Zito JM: Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: Children versus adolescents. J Child Adolesc Psychopharmacol 16:159-169, 2006.
125. Saias T, Gallarda T: Paradoxical aggressive reactions to benzodiazepine use: A review. Encephale 34:330-336, 2008.
126. Scharko AM, Reiner WG: SSRI-induced sexual dysfunction in adolescents. J Am Acad Child Adolesc Psychiatry 43:1067, 2004.
127. Schuckit MA, Smith TL: Changes over time in the self-reported level of response to alcohol. Alcohol Alcohol 39:433-438, 2004.
128. Seroquel FDA Approved Label: 12/2/2009. pp. 21, 22, 35, 47 and 50. Available at www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 020639s045s046lbl.pdf (accessed 3/11).
129. Seroquel FDA Pediatric/Advisory Committee: Briefing information for the December 8, 2009 meeting. pp. 47 and 56. Available at www.fda.gov/ AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/ ucm166530.htm
130. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA: A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsychopharmacology 29:133-145, 2004.
131. Silva RR, Campbell M, Golden RR, Small AM, Pataki CS, Rosenberg CR: Side effects associated with lithium and placebo administration in aggressive children. Psychopharmacol Bull 28: 319-326, 1992.
132. Silvetti MS, Drago F, Ragonese P: Heart rate variability in healthy children and adolescents is partially related to age and gender. Int J Cardiol 81:169-174, 2001.
133. Simeon JG, Ferguson HB, Knott V, Roberts N, Gauthier B, Dubois C, Wiggins D: Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. J Am Acad Child Adolesc Psychiatry 31:29-33, 1992.
134. Simpson D, Plosker GL: Atomoxetine: A review of its use in adults with attention deficit hyperactivity disorder. Drugs 64:205-222, 2004.
135. Snider LA, Seligman LD, Ketchen BR, Levitt SJ, Bates LR, Garvey MA, Swedo SE: Tics and problem behaviors in school children: Prevalence, characterization, and associations. Pediatrics 110:331-336, 2002.
136. Sonuga-Barke EJ, Coghill D, Wigal T, Debacker M, Swanson J: Adverse reactions to methylphenidate treatment for attention-deficit/ hyperactivity disorder: Structure and associations with clinical characteristics and symptom control. J Child Adolesc Psychopharmacol 19:683-690, 2009.
137. Spencer TJ, Biederman J, Wilens T, Faraone S, Prince J, Gerard K, Doyle R, Parekh A, Kagan J, Bearman SK: Efficacy of a mixed amphetamine salts compound in adults with attentiondeficit/ hyperactivity disorder. Arch Gen Psychiatry 58:775-782, 2001.
138. Spencer TJ, Faraone SV, Morgan JA, Mays DA, Michaels MA, Tulloch S: A cohort analysis of measured growth parameters in children with attention-deficit hyperactivity disorder receiving mixed amphetamine salts (MAS XR) for 24 months. Poster presented at the annual meeting of New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL, June 2004.
139. Spencer TJ, Newcorn JH, Kratochvil CJ, Ruff D, Michelson D, Biederman J: Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder. Pediatrics 116:e74-e80, 2005.
140. Sporn A, Gogtay N, Ortiz-Aguayo R, Alfaro C, Tossell J, Lenane M, Gochman P, Rapoport JL: Clozapine-induced neutropenia in children: Management with lithium carbonate. J Child Adolesc Psychopharmacol 13:401-404, 2003.
141. Sporn AL, Vermani A, Greenstein DK, Bobb AJ, Spencer EP, Clasen LS, Tossell JW, Stayer CC, Gochman PA, Lenane MC, Rapoport JL, Gogtay N: Clozapine treatment of childhood-onset schizophrenia: Evaluation of effectiveness, adverse events, and long-term outcome. J Am Acad Child Adolesc Psychiatry 46:1349-1356, 2007.
142. Stein MA: Oros methylphenidate for treatment of adolescents and adults with ADHD. Poster presented at the annual meeting of the Am Acad Child Adolesc Psychiatry, Miami, FL, October 18, 2003.
143. Strattera FDA Approved Label: 12/22/2009. pp. 7 and 19. Available at www.accessdata.fda.gov/drugsatfda-docs/label/2009/021411s029s030lbl.pdf (accessed 3/11).
144. Swanson J, Greenhill L, Wigal T, Kollins S, Nguyen A, Davies M: Stimulant-related growth suppression in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry 45:1304-1313, 2006.
145. Swanson J, Kraemer H, Stehli A, Wigal T, Hinshaw S, Arnold LE Molina B, Greenhill LL: Long-term follow-up on the multimodal treatment study of ADHD: Effects of assigned treatment and selfselected medication use on ultimate height, weight and BMI. Paper presented at the 56th annual meeting of the Am Acad Child Adolesc Psychiatry, Hawaii, HI, October 29, 2009.
146. Swanson JM, Elliott GR, Greenhill LL, Wigal T, Arnold LE, Vitiello B, Hechtman L, Epstein N, Pelham WE, Abikoff HB, Newcorn JH, Molina BS, Hinshaw SP, Wells KC, Hoza B, Jensen PS, Gibbons RD, Hur K, Stehli AM, Davies M, March JS, Conners CK, Caron M, Volkow ND: Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 46:1015-1027, 2007.
147. Topamax FDA Safety Alert: 7/1/2003. Available at www.fda.gov/ Safety/Medwatch/SafetyInformation/SafetyAlertsforHumanMedical Products/ucm169486.htm (accessed 3/11).
148. Topamax FDA Approved Label: 12/22/2009. pp. 17-18. Available at www.accessdata.fda.gov/drugsatfda-docs/label/2009/020505s038 s039,020844s032s034lbl.pdf (accessed 3/11).
149. Vainionpaa LK, Rattya J, Knip M, Tapanainen JS, Pakarinen AJ, Lanning P, Tekay A, Myllyla VV, Isojarvi JI: Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 45:444-450, 1999.
150. Varley CK, Vincent J, Varley P, Calderon R: Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medications. Compreh Psychiat 42:228-233, 2001.
151. Wagner KD, Kowatch RA, Emslie GJ, Findling RL, Wilens TE, McCague K, D'Sousa, J, Wamil A, Lehman RB, Berv D, Linden D: A double-blind, randomized, placebo-controlled trial of ozcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 163:1179-1186, 2006.
152. Weintraub D, Buchsbaum R, Resor SR, Hirsh LJ: Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy Behav 10:105-110, 2007.
153. Weiss B: Vulnerability of children and the developing brain to neurotoxic hazards. Environ Health Perspect 108 (Suppl 3):375-381, 2000.
154. Wender PH, Reimherr FW, Marchant BK, Sanford ME, Czajkowski LA, Tomb DA: A one year trial of methylphenidate in the treatment of ADHD. J Atten Disord 15:36-45, 2011.
155. Werneke U, Northey S, Bhugra D: Antidepressants and sexual dysfunction. Acta Psychiatr Scand 114:384-397, 2006.
156. Wigal T, Greenhill L, Chuang S, McGough J, Viteillo B, Skrobala A, Swanson J, Wigal S, Abikoff H, Kollins S, McCracken J, Riddle M, Posner K, Ghuman J, Davies M, Thorp B, Stehli A: Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry 45:1294-1303, 2006.
157. Wilens TE, Biederman J, Spencer TJ, Prince J: Pharmacotherapy of adult attention deficit/hyperactivity disorder: A review. J Clin Psychopharmacol 15:270-279, 1995.
158. Wilens TE, Kratochvil C, Newcorn JH, Gao H: Do children and adolescents with ADHD respond differently to atomoxetine? J Am Acad Child Adolesc Psychiatry 45:149-157, 2006.
159. Witkop CJ, Wolf RO: Hypoplasia and intrinsic staining of enamel following tetracycline therapy. JAMA 185:1008-1011, 1963.
160. Wiznitzer M, Findling RL: Why do psychiatric drug research in children? Lancet 361:1147-1148, 2003.
161. Wolf SM, Shinnar S, Kang H, Gil KB, Moshe SL: Gabapentin toxicity in children manifesting as behavioral changes. Epilepsia 36:1203-1205, 1995.
162. Woods, SW, Martin A, Spector SG, McGlashan TH: Effects of development on olanzapine-associated adverse events. J Am Acad Child Adolesc Psychiatry 41:1439-1446, 2002.
163. Yazdani K, Lippmann M, Gala I: Fatal pancreatitis associated with valproic acid: Review of the literature. Medicine 81:305-310, 2002.
164. Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH, Tsai CH: Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 350:1304-1313,2004.
165. Yeragani VK, Pohl R, Berger R, Balon R, Srinvasan K: Relationship between age and heart rate variabiity in supine and standing postures: A study of spectral analysis of heart rate. Pediat Cardiol 15:14-20, 1994.
166. Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, Pauslsson B, Brecher M: A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 71:150-162, 2010.
167. Young JG, Cohen DJ, Anderson GM, Shaywitz BA: Neurotransmitter ontogeny as a perspective for studies of child development and pathology. In: The Psychobiology of Childhood. Edited by L. Greenhill, Shopsin B. New York: Spectrum Publications; 1984; pp. 51-84.
168. Zonisamide FDA Safety Alert: Information for healthcare professionals 2/23/2009. Available at www.fda.gov/Safety/Medwatch/ SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm106934.htm (accessed 10/27/2010).